Kidney Cancer Coverage from Every Angle

Rare Liposarcoma Associated With Renal Cell Carcinoma: Case Report

By: Hillary Ojeda
Posted: Wednesday, February 26, 2020

South American investigators have studied what they consider to be the first reported case of clear cell renal cell carcinoma synchronous with dedifferentiated liposarcoma of a limb, according to a report published in the Journal of Medical Case Reports. Angela R. Zambrano, MD, of the Fundación Valle del Lili, Cali, Colombia, and colleagues suggest in their case presentation and literature review that further genetic tests and studies on the tumors are necessary to understand the unique association.

“Our case is especially rare. Dedifferentiated liposarcoma only behaves as a metastatic disease in about 15% of cases; most patients develop this tumor in the retroperitoneum, with very few cases developing in the limbs,” according to the authors.

The patient, a 62-year-old man, presented at an outpatient center in the orthopedic surgery unit at the Fundación Valle del Lili with pain and a developing mass in his left thigh. After an examination and an initial finding of hemorrhage, a second biopsy was done. Tissue with a neoplastic lesion of mesenchymal origin was identified alongside hemorrhage and tumor necrosis, high-grade pleomorphic sarcoma with giant cells, and mitosis compatible with dedifferentiated liposarcoma. The patient was given several treatment lines, but with no response, and metastatic transformation continued. Genetic testing revealed four pathogenic mutations that could not be treated with targeted therapy (BRCA2, NF1, RB1, TP53). At the time of the report’s publication, the investigators said the patient was undergoing palliative care due to his nonresponsive metastatic disease.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.